Biocon Biologics settles with Janssen; paves way for launch of biosimilar in US

Biocon Biologics signs settlement and license agreement with Janssen Biotech and Johnson & Johnson to commercialize Bmab 1200, a biosimilar to Stelara, in the US once approved by the USFDA. The therapy is expected to launch in February 2025.

Feb 29, 2024 - 20:00
Biocon Biologics settles with Janssen; paves way for launch of biosimilar in US
Biocon Biologics signs settlement and license agreement with Janssen Biotech and Johnson & Johnson to commercialize Bmab 1200, a biosimilar to Stelara, in the US once approved by the USFDA. The therapy is expected to launch in February 2025.